ASH 2020: Single Dose of Etranacogene Dezaparvovec Increases Factor IX Activity and Reduces Bleeding Risk in Hemophilia B
Findings represent another step toward use of gene therapy as standard of care for certain forms of hemophilia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.